Английская Википедия:Fosmanogepix
Шаблон:Short description Шаблон:Cs1 config Шаблон:Infobox drug
Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals (now currently by Pfizer and Basilea[1][2]) It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis.[3]
Fosmanogepix is a prodrug and is converted into the active drug form, manogepix, after administration.[4] Manogepix targets the enzyme GWT1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1[5]), an enzyme in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway.[6] Inhibiting this enzyme prevents the fungi from properly modifying certain (GPI-anchored) proteins essential to its life cycle. This mechanism of action is totally novel; therefore, if approved, fosmanogepix would become a first-in-class medication.[6][7]
In 2023, the drug was given a compassionate use authorization for four patients with iatrogenic Fusarium solani infections.[8]
References
Шаблон:Antiinfective-drug-stub
